ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1790

Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort

Murray Urowitz1, Dafna D Gladman2, Nicole Anderson3, Jiandong Su4 and The Systemic Lupus International Collaborating Clinics (SLICC) Group, 1Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Atherosclerosis, Comorbidity, osteonecrosis, osteoporosis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described.  We report the annual occurrence of these features in an inception cohort of patients with SLE.

Methods: An international research network comprised of 33 centres from 11 countries has followed an inception cohort of SLE patients yearly according to a standardized protocol between 2000 and 2016. Of these, 717 patients followed for a minimum of 8 years constitute the study population.  Comorbidities including atherosclerotic vascular events (AVEs), osteoporosis, osteonecrosis and diabetes are assessed using the SLICC/ACR Damage Index (SLICC/DI). AVEs are described and attributed on a specialized form. Diagnosis of an event is confirmed using standard clinical criteria, relevant laboratory data and imaging where appropriate. Attribution to atherosclerosis is made on the basis of lupus disease being inactive at the time of the event, and/or the presence of typical atherosclerosis (AS) changes on imaging or pathology and/or evidence of AS elsewhere. Diagnosis of osteoporosis is based on abnormal bone mineral density and osteonecrosis was based on joint symptoms associated with abnormal imaging consistent with osteonecrosis. Diabetes diagnosis is based on therapy, regardless of treatment type. Descriptive statistics were used.

Results: Of the 717 patients followed for at least 8 years, 90.2% were female, 47.3% were Caucasian, 13.8% were Black, 19.4% were Asian, 16.3% Hispanic and 3.2% other.  Their mean age at enrolment was 34.2±13.1 years and SLEDAI-2K at enrolment was 4.17±4.49. The duration from diagnosis to enrolment was 5.9±4.4 months. Table 1.  Cumulative SDI, AVEs, Osteoporosis, Osteonecrosis and Diabetes in the first 8 Years of Follow-up (n=717)

Follow-up

SDI

(mean±std)

AVE

Osteoporosis

Osteonecrosis

Diabetes

1

0.3±0.7

4 (0.5%)

3 (0.4)

3 (0.4%)

13 (1.8%)

2

0.5±1.0

5 (0.7%)

5 (0.7%)

10 (1.4%)

17 (2.4%)

3

0.6±1.2

10 (1.4%)

7 (1.0%)

15 (2.1%)

17 (2.4%)

4

0.7±1.2

13 (1.8%)

10 (1.4%)

18 (2.5%)

19 (2.7%)

5

0.8±1.3

18 (2.5%)

11 (1.5%)

21 (2.9%)

19 (2.7%)

6

1.0 ±1.4

20 (2.8%)

15 (2.1%)

25 (3.5%)

21 (2.9%)

7

1.0±1.4

21 (2.9%)

17 (2.4%)

27 (3.8%)

22 (3.1%)

8

1.1±1.5

25 (3.5%)

19 (2.7%)

31 (4.3%)

25 (3.5%)

    Table 2. Cumulative Comorbidities by Year in Caucasians Compared to All Other Ethnicities

 

Follow up years since SLE diagnosis

Comorbidity

1

2

3

4

5

6

7

8

AVE Caucasian (%) 0.59 0.88 2.06 2.95 3.54 4.13 4.42 5.60
AVE Other (%) 0.53 0.53 0.79 0.79 1.59 1.59 1.59 1.59
Osteoporosis Caucasians (%) 0.00 0.59 1.18 1.77 2.06 3.25 3.55 4.14
Osteoporosis Others (%) 0.79 0.79 0.79 1.06 1.06 1.06 1.32 1.32
Osteonecrosis Caucasians (%) 0.59 1.18 1.18 1.47 1.47 2.07 2.07 2.66
Osteonecrosis Others (%) 0.26 1.59 2.91 3.44 4.23 4.76 5.29 5.82
Diabetes Caucasian (%) 1.77 2.65 2.65 2.95 2.95 2.96 2.96 3.25
Diabetes Other (%) 1.85 2.12 2.12 2.38 2.38 2.91 3.17 3.70

  Mean SDI gradually increases over 8 years. The accumulation of AVEs, osteoporosis, osteonecrosis and diabetes all increase progressively over an 8-year period.  Caucasians accumulate AVEs and osteoporosis more frequently than all “other” ethnicities. In contrast, all “other” ethnicities accumulate osteonecrosis more frequently than Caucasians. All ethnicities accumulate diabetes at the same frequency.

Conclusion: As expected disease damage and comorbidities in newly diagnosed patients increase over their first 8 years. Different ethnicities accumulate comorbidities at different rates


Disclosure: M. Urowitz, None; D. D. Gladman, None; N. Anderson, None; J. Su, None.

To cite this abstract in AMA style:

Urowitz M, Gladman DD, Anderson N, Su J. Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/accrual-of-disease-comorbidities-over-8-years-in-a-multicentre-inception-sle-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/accrual-of-disease-comorbidities-over-8-years-in-a-multicentre-inception-sle-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology